Chronic chikungunya disease (CCD): clinical insights, immunopathogenesis, and therapeutic perspectives
- Published on 07/01/2025
- Reading time: 4 min.
Wern Hann Ng, 1,2,3, Kennedy Amaral, 4, Emilie Javelle, 5,6,7,8, Suresh Mahalingam 1,2,3
1 Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University, QLD, 4222, Australia
2 Global Virus Network (GVN) Centre of Excellence in Arboviruses, Griffith University, Gold Coast, QLD, Australia
3 School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD, Australia
4 Federal University of Cariri, Barbalha, Ceará, Brazil
5 Unité parasitologie et entomologie, Département Microbiologie et Maladies Infectieuses, Institut de recherche biomédicale des armées, Marseille, France
6 Aix Marseille Univ, IRD, SSA, AP-HM, VITROME, Marseille, France
7 IHU Méditerranée Infection, Marseille, France
8 Hôpital d'instruction des armées Laveran, Marseille
Joint corresponding authors: Address correspondence to Prof. Suresh Mahalingam, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Parklands Drive, Southport, Gold Coast, 4222, Queensland, Australia, Phone: +61 7 56780664, email:s.mahalingam@griffith.edu.au or Mr Wern Hann Ng, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Parklands Drive, Southport, Gold Coast, 4222, Queensland, Australia, email: wernhann.ng@griffithuni.edu.au
To continue reading this article in Full-Text...
Join the Valneva community to receive personalized information as specified in the Valneva Privacy Policy available here about Valneva services, product events and programs by email.
I WANT TO BE A MEMBER
Search | Advanced search
Articles by topics
